Heat Biologics seeks FDA nod to test bladder cancer candidate

10/3/2013 | Pharmaceutical Business Review Online

Heat Biologics submitted an investigational new drug application to the FDA for approval to test its second drug candidate, HS-410, in patients with bladder cancer. Heat announced that the HS-410 program and all of the firm's clinical trials will be supervised by Melissa Price, the company's new vice president of clinical and regulatory affairs.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC